In May 2022, about a month before Julie Burkhart and her team planned to open Wyoming’s only full-service abortion clinic, an arsonist set fire to the building. But that didn’t stop Burkhart ...

“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” said Governor Maura Healey, in a statement. “We are thrilled to see them ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Jefferies downgraded Biogen from Buy to Hold, setting a new price target of $180, down from $250. Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition.

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet. The Cambridge, Massachusetts ...

Biotechnology company Biogen is abandoning Aduhelm, its questionable Alzheimer's drug that has floundered on the market since its scandal-plagued regulatory approval in 2021 and brow-raising pricing.

Biogen’s decision to move on from Aduhelm closes the book on what was once projected to be a major blockbuster drug, but it ended up the center of a controversy that eroded trust in the FDA’s ...

Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer's in nearly two decades. The pharmaceutical giant is ...

Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...

Biogen Inc (NASDAQ:BIIB) experienced a daily loss of 1.56% and a three-month loss of 10.51%. Despite these losses, the company's Earnings Per Share (EPS) (EPS) stands at 18.37. This raises the ...

It was only last spring that Biogen started a round of layoffs that eventually shrank the company’s head count by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 ...

Biogen Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio. Biogen will pay $172.50 per share for Reata, a 59% premium to Thursday's ...